Mixed-ancestry genetic research shows a bit of Native American DNA could reduce risk of Alzheimer’s disease – The Conversation US

Since the human genome was first mapped, scientists have discovered hundreds of genes influencing illnesses like breast cancer, heart disease and Alzheimers disease. Unfortunately, Black people, Indigenous people and other people of color are underrepresented in most genetic studies. This has resulted in a skewed and incomplete understanding of the genetics of many diseases.

We are two researchers who have been working to find genes that affect peoples risk for various diseases. Our team recently found a genetic region that appears to be protective against Alzheimers disease. To do this, we used a method called admixture mapping that uses data from people with mixed ancestry to find genetic causes of disease.

In 2005, researchers first used a groundbreaking method called a genomewide association study. Such studies comb through huge datasets of genomes and medical histories to see if people with certain diseases tend to share the same version of DNA called a genetic marker at specific spots.

Using this approach, researchers have identified many genes involved in Alzheimers disease. But this method can find genetic markers only for diseases that are common in the genomes of the study participants. If, for example, 90% of participants in an Alzheimers disease study have European ancestry and 10% have Asian ancestry, a genome-wide association study isnt likely to detect genetic risks for Alzheimers disease that are present only in individuals with Asian ancestry.

All peoples genetics reflect where their ancestors came from. But ancestry manifests as both genetic variation and social and cultural experiences. All of these factors can influence risk for certain diseases, and this can create problems. When socially caused disparities in disease prevalence appear across racial groups, the genetic markers of ancestry can be mistaken for genetic markers of disease.

African Americans, for example, are up to twice as likely as white Americans to develop Alzheimers disease. Research shows that much of this disparity is likely due to structural racism causing differences in nutrition, socioeconomic status and other social risk factors. A genome-wide association study looking for genes associated with Alzheimers might mistake genetic variations associated with African descent for genetic causes of the disease.

While researchers can use a number of statistical methods to avoid such mistakes, these methods can miss important findings because they are often unable to overcome the overall lack of diversity in genetic datasets.

Disentangling race, ancestry and health disparities can be a challenge in genome-wide association studies. Admixture mapping, on the other hand, is able to make better use of even relatively small datasets of underrepresented people. This method specifically gets its power from studying people who have mixed ancestry.

Admixture mapping relies on a quirk of human genetics you inherit DNA in chunks, not in a smooth blend. So if you have ancestors from different parts of the world, your genome is made of chunks of DNA from different ancestries. This process of chunked inheritance is called admixture.

Imagine color-coding a genome by ancestry. A person who has mixed European, Native American and African ancestry might have striped chromosomes that alternate among green, blue and red, with each color representing a certain region. A different person with similar ancestry would also have a genome of green, blue and red chunks, but the order and size of the stripes would be different.

Even two biological siblings will have locations in their genomes where their DNA comes from different ancestries. These ancestry stripes are how companies like Ancestry.com and 23andMe generate ancestry reports.

Because genome-wide association studies have to compare huge numbers of tiny individual genetic markers, it is much harder to find rare genetic markers for a disease. In contrast, admixture mapping tests whether the color of a certain ancestry chunk is associated with disease risk.

The statistics are fairly complicated, but essentially, because there are a smaller number of much larger ancestral chunks, it is easier to separate the signal from the noise. Admixture mapping is more sensitive, but it does sacrifice specificity, as it cant point to the individual genetic marker associated with disease risk.

Another important aspect of admixture mapping is that it looks at individuals with mixed ancestry. Since two people who have similar socioeconomic experiences can have different ancestry at certain parts of their genomes, admixture mapping can look at the association between this ancestry chunk and disease without mistaking social causes of disease for genetic causes.

Researchers estimate that 58% to 79% of Alzheimers disease risk is caused by genetic difference, but only about a third of these genetic differences have been discovered. Few studies have looked for genetic links to Alzheimers risk among people with mixed ancestry.

Our team applied admixture mapping to a genetic dataset of Caribbean Hispanic people who have a mix of European, Native American and African ancestry. We found a part of the genome where Native American ancestry made people less likely to have Alzheimers disease. Essentially, we found that if you have the color blue in this certain part of your genome, you are less likely to develop Alzheimers disease. We believe that with further research we can find the specific gene responsible within the blue chunk and have already identified possible candidates.

One important note is that the genetic diversity that plays a role in disease risk is not visible to the naked eye. Anyone with Native American ancestry at this particular spot in the genome not just a person who identifies as or looks Native American may have some protection against Alzheimers disease.

Our paper illustrates that gaining a more complete understanding of Alzheimers disease risk requires using methods that can make better use of the limited datasets that exist for people of non-European ancestry. There is still a lot to learn about Alzheimers disease, but every new gene linked to this disease is a step toward better understanding its causes and finding potential treatments.

See the original post here:
Mixed-ancestry genetic research shows a bit of Native American DNA could reduce risk of Alzheimer's disease - The Conversation US

3 Things About Fulgent Genetics That Smart Investors Know – Motley Fool

During the COVID-19 pandemic, Fulgent Genetics (NASDAQ:FLGT) was in the right place at the right time. Fulgent became a key provider of COVID-19 testing in 2020 and saw its revenue explode by almost 1,300% over the prior year. Few companies benefited more during the pandemic -- and few have a bigger cloud of uncertainty hanging over them as investors worry about what comes next.

The good news is that Fulgent isn't a one-trick pony. The company is going through a metamorphosis, strengthened by a reinforced balance sheet and a growing core business in an attractive genetic testing market. Investors should prepare to shift their perspective.

Image source: Getty Images.

Before the COVID-19 testing opportunity came along, Fulgent's core business was a small but fast-growing next generation sequencing (NGS) genetic testing service primarily focused on pediatric rare diseases.

That segment is still expanding fast. In the first quarter ended March 31, NGS volume grew 185% year over year from 13,000 to 38,000 tests, while corresponding revenue grew 115% to $16.7 million. Management is projecting NGS revenue of over $100 million in 2021, representing 170% year-over-year growth.

Fulgent has an efficient technology and operating platform generating gross margins of about 80% and operating margins above 70%. As a result, liquidity is a real bright spot for Fulgent. At the end of Q1, it reported $697 million in cash, cash equivalents, and marketable securities. Management expects to close the year with more than $1 billion in short-term liquidity, excluding any merger- and acquisition-related activity.

The encouraging growth in the core business is understandably offset by a rapid reduction in COVID-19 testing revenue. Unless there is a flare-up of infections from virus variants, COVID-19 testing revenue will continue to fall dramatically. Management is projecting $418 million in COVID-19 testing revenue for the remainder of the year, compared with $312 million in Q1 alone.

This precipitous revenue falloff is an operational challenge, but Fulgent has an experienced management team that over the past year has proven to be strong operators in building and scaling the business.

Fulgent will report quarterly earnings in early August. Smart investors will keep an eye on these three areas for signs management is executing on the long-term growth potential:

1. Continued COVID-19 testing

While testing volumes are declining, the endpoint is not zero. Fulgent has proven to be a high-quality, low-cost, fast-turnaround provider of gold-standard RT-PCR tests. Many screening programs are not allowing less sensitive antigen or rapid molecular tests to be used. As a result, Fulgent has been able to secure contracts for "return to normalcy" testing, particularly with school systems and the government.

The Department of Health and Human Services announced it will invest $12 billion in COVID-19 testing through the American Rescue Plan, with $10 billion going to schools. Fulgent management estimates that more than 1 million tests per day will be needed with this new program. Look for contract wins and continued testing volume in the near term.

2. Growth catalysts

Fulgent is expanding into additional genetic testing areas, including hereditary cancer, which is a high-growth area. There are more than 550 ongoing clinical trials for oncology genetic therapies, which will drive the need for more genetic testing and higher reimbursement over the coming years. Pharma companies are advocating and paying for genetic testing, since it will drive demand for their therapies. Fulgent has also established FF Gene Biotech, a joint venture focused on oncology in China, which is expected to be a $45 billion market. Stay tuned to these critical long-term developments.

3. Mergers and acquisitions

Fulgent's large cash position and strong operating leverage could make acquisitions a way to rapidly generate revenue that is accretive to the bottom line. In last year's Q4 conference call, CEO Ming Hsieh called out his interest in acquisitions to expand the core diagnostic business in Asia and Europe. It's a big world, and billions of people will need the genetic tests Fulgent is developing.

The market doesn't like uncertainty, which has helped push Fulgent shares down 56% from their 52-week high. The share price may go even lower as investors struggle to understand the profit picture in the next few quarters.

For patient long-term buy-and-hold investors with a tolerance for some uncertainty, Fulgent Genetics may actually be the best value biotech stock out there and could be a great addition for your portfolio.

This article represents the opinion of the writer, who may disagree with the official recommendation position of a Motley Fool premium advisory service. Were motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Follow this link:
3 Things About Fulgent Genetics That Smart Investors Know - Motley Fool

Patients With a Combination of ADHD and DBD Share Genetic Factors Linked to Risky, Aggressive Behavior – Pharmacy Times

Individuals with both attention-deficit/hyperactivity disorder (ADHD) and a disruptive behavior disorder (DBD) share about 80% of genetic variants associated with aggressive and antisocial behaviors, according to new research published in Nature Communications. The study analyzed nearly 4000 patients with these pathologies and 30,000 control individuals, examining the neurobiological basis for aggressive behavior.

Certain people feature 2 or more psychiatric disorders, and this coexistence continues, in many cases, in a chronological axis, in which suffering from a psychiatric disorder such as ADHD involves opening the door to other comorbid pathologies that aggravate the life quality of those who suffer from the disorder, said Marta Ribass, PhD, head of the Laboratory of Genetic Psychiatry of Vall d'Hebrn Research Institute (VHIR), in a press release.

ADHD affects around 5% of children and 2.5% of adults and features hyperactivity, impulsiveness, and attention deficit. It is often associated with additional psychiatric conditions, including DBDs, which can be associated with antisocial and aggressive behaviors.

ADHD and DBD are caused by genetic and environmental factors, said Bru Cormand, professor at the Department of Genetics, Microbiology and Statistics and head of the Research Group on Neurogenetics at the University of Barcelona, in the release. Regarding ADHD, it is estimated that genetics account for 75%, while in DBDs, it would oscillate between 40 and 70%. These clinical pictures are more frequent in boys than girls, and when they come together, people are more likely to fall into risky behaviors, addictive substance use, and premature death.

The investigators identified a genomic segment in chromosome 11 that increases the risk of having ADHD in combination with DBD. This region contains the STIM1 gene, responsible for the regulation of calcium cell levels, neuronal plasticity and learning memory.

Our study shows that genetics are more determining in people with ADHD and DBD than those who only suffer from ADHD, Cormand said in the release. If we compare the genome of patients with ADHD and DBD to that of those patients with only ADHD, we see that people affected by both disorders have a higher genetic correlation with risk genetic variants. These extra correlations of [patients with] ADHD and DBD would probably correspond to alterations other authors had related to aggressive-related behaviors.

According to the investigators, this study will help broaden the understanding of the genetic landscape of ADHD comorbidities, enabling the prediction of potential secondary complications for these patients.

If we consider ADHD to be an open door to a negative trajectory, using genetic information to identify those individuals who are more vulnerable will have a strong impact on prevention, early detection, and treatment, and will shed light on new research studies to find efficient therapies that can be specific for the disorder or shared between several disorders, Ribass said in the release.

REFERENCE

ADHD, DBD and aggressiveness: Risky genetic factors [news release]. EurekAlert; February 17, 2021. Accessed July 13, 2021. https://www.eurekalert.org/pub_releases/2021-02/uob-ada021721.php

Continue reading here:
Patients With a Combination of ADHD and DBD Share Genetic Factors Linked to Risky, Aggressive Behavior - Pharmacy Times

Getting to the heart of genetic cardiovascular diseases | Penn Today – Penn Today

When she isnt pursuing her favorite heart-pumping activities of running, swimming, or cycling, Sharlene M. Day, a presidential associate professor of cardiovascular medicine and director of Translational Research for the Penn Cardiovascular Institute, is focused on the heart in another way; trying to unlock and treat the mysteries of genetic heart disease.

As part of her research at the Day Lab, Day integrates translational and clinical science to understand the full spectrum of genetic heart disease evolution and progression, from gene mutations in heart muscle cells to ways of predicting negative outcomes in patients. Clinically, she sees patients with hypertrophic cardiomyopathy, a condition where the heart muscle becomes thick making it harder for blood to leave the heart, and other genetic heart conditions at the Penn Center for Inherited Cardiac Disease, such as inherited arrhythmias, high blood cholesterol, Marfan syndrome and familial amyloidosis. Her research program primarily focuses on these same conditions.

A physician scientist, Day completed her residency, followed by a cardiology fellowship, and a postdoctoral research fellowship at the University of Michigan before joining the faculty there, and spent 24 years there before coming to Penn. Day was recruited to Penn Medicine to lead initiatives in translational research within the Cardiovascular Institute and to grow the clinical and academic mission in the Penn Center for Inherited Cardiovascular Disease.

Very early on in my training, I became fascinated with the interplay between genetics and cardiac physiology that manifest in very unique observable cardiac traits and complicated disease trajectories including both heart failure and arrhythmias, also known as irregular heartbeats, says Day.

This story is by Sophie Kluthe. Read more at Penn Medicine News.

Read more:
Getting to the heart of genetic cardiovascular diseases | Penn Today - Penn Today

Lecturer/Senior Lecturer in Genetics job with UNIVERSITY OF GREENWICH | 260037 – Times Higher Education (THE)

School of Science

Location: Medway campusSalary: 33,797 to 49,553 per annumContractType: PermanentClosingDate: Monday 09 August 2021InterviewDate: To be confirmedReference: 2755-E

The School of Science (www.gre.ac.uk/es/science) at the University of Greenwich is a large interdisciplinary School, covering biological sciences, biomedical sciences, food and nutrition, chemistry, pharmaceutical sciences, and forensic science. We have ambitious research and teaching plans as part of our new University Strategy This is our time to ensure that our students are fully prepared for future careers. Collegiality and interdisciplinary research and teaching are key features of the School. Our School is based at the historic Medway campus and boasts amazing learning spaces with state-of-the-art laboratories and lecture theatres.

As part of our ongoing development and expansion of biological, biomedical sciences and forensic science provision within the University, we are seeking to appoint a permanent lecturer/senior lecturer (teaching & research) in genetics (broadest sense). The post holder will have a strong track record at the national and international levels and will establish their own independent research programme. For appointment as Senior Lecturer, you will also have a proven track record of attracting external research and other grants.

Applicants will also be expected to contribute high quality teaching within the School and will be responsible for lectures, tutorials and laboratory classes on the biology, biomedical sciences and forensic sciences degree programmes, as well as academic duties including student assessment, marking and pastoral support. Further, with molecular techniques routinely used for diagnosis and investigation within biosciences and forensics, we seek to appoint a geneticist with knowledge and experience in these methods.

This is an exciting opportunity for a suitably motivated individual to help shape the future of bioscience research and teaching provision within the School.

The post will be based in the School of Science on the Medway campus.

For informal enquiries, please contact the Head of School, Professor Adrian Dobbs onA.Dobbs@gre.ac.uk

Should you have any queries please contact the HR Recruitment Team onHR-Recruitment@gre.ac.uk

We are looking for people who can help us deliver our mission of transforming lives through inspired teaching and research, through ourvalues.

The university welcomes people from diverse and underrepresented communities who can help the university to achieve its mission.

We do this through taking positive action such as encouraging applications from Black, Asian and Minority Ethnic, disabled and LGBT+ people. As part of our commitment to Equality, Diversity and Inclusion, Time to Change Employer Pledge/Mentally Healthy Universities, we are committed to promoting and supporting the physical and mental health of all our staff and removing barriers to improve inclusion.

We encourage applicants to disclose experience of mental health problems so we can support them fully during our recruitment process and make any necessary reasonable adjustments. Any information disclosed will be kept confidential and separate from the job application form.

We are making significant strides to understand and continuously improve our employees experience and we are committed to implementing progressive diversity talent management.

See more here:
Lecturer/Senior Lecturer in Genetics job with UNIVERSITY OF GREENWICH | 260037 - Times Higher Education (THE)

COVID-19 Roundup: The Unvaccinated Fuel Hospitalizations; Genetic Link to Severe Illness; and Children’s Infection Rate – Baptist Health South Florida

This Virus Will Evolve: Concerns Grow Over Variants, New Surge Among the Unvaccinated

Just as public health officials feared, the combination of too many unvaccinated people and the more contagious delta strain of the coronavirus has led to new COVID-19 surges across the nation.

The vast majority of patients being hospitalized now for COVID-19 are unvaccinated, explains Sergio Segarra, M.D., the chief medical officer with Baptist Hospital, part of Baptist Health South Florida. And many of them are young adults in their 20s and 30s who are getting extremely sick.

Sergio Segarra, M.D., chief medical officer with Baptist Hospital, part of Baptist Health South Florida.

From the very beginning, that was a concern of mine that we do not get a substantial portion of the population vaccinated, said Dr. Segarra, who was interviewed by CNN this week on the latest surge in COVID-19 hospitalizations in Florida and nationwide.

The latest update from the Florida Health Department shows that 58 percent of the states population over the age of 12 has been vaccinated. Among the most populated South Florida counties, Miami-Dade registered a 73 percent vaccination rate; Broward 66 percent, and Palm Beach 62 percent, according to the latest data.

But there is a persistent group of people who, for whatever reason, are not getting vaccinated. The more people that get infected, the greater the likelihood that the virus evolves into more variants, said Dr. Segarra.

On Thursday, U.S. Surgeon General Vivek Murthy, M.D, released the first surgeon generals advisory of his time with the Biden administration, describing the urgent threat posed by the rise of false information about COVID-19 and vaccines. Misinformation has caused confusion and led people to decline COVID-19 vaccines, reject public health measures such as masking and physical distancing, and use unproven treatments, states the advisory.

The U.S. Centers for Disease Control and Prevention said this week that the delta variant is responsible for 58 percent of newly confirmed cases nationwide from June 20 through July 3. The COVID-19 vaccines approved for use in the U.S. effectively protects people from severe illness if they are infected with the delta strain of the virus, the CDC says.

With more people getting the virus, whether they get minor symptoms or get significantly ill and end up in the hospital, theres a greater chance that a variant is going to occur, explains Dr. Segarra. The virus will evolve.

The worse-case scenario, which fortunately has not occurred, says Dr. Segarra, is the emergence of a variant that is resistant to the currently available vaccines.

That hasnt happened yet, but thats something that does keep me up, says Dr. Segarra. Thats something that makes me worry. And I would hate to think that 10 years from now theyre going to say, Wow, those people back in 2021 could have gotten the vaccine, but they didnt. And now theres some terrible variant out there that is creating all kinds of havoc. So, that does worry me.

For more than a year since the beginning of the pandemic, researchers and clinicians have been trying to understand why some people develop severe COVID-19 illness, while others show few if any symptoms. Risk factors have included age and underlying medical conditions.

However, variations in the human genome have not been thoroughly investigated as a possible risk factor that determines a mild or severe response to a COVID-19 infection. That is, until now.

A new study published in Nature, led by the COVID-19 Host Genomics Initiative (HGI), confirms or newly identifies 13 genes that appear to play a role in susceptibility to the coronavirus, or that have an affect on the severity of illness. The researchers established international collaboration when the pandemic started to focus on genetics. This collaboration included about 3,000 researchers and clinicians and data from 46 studies involving more than 49,000 individuals with COVID-19.

HGI teams involved in the analysis include both academic laboratories and private firms from two dozen countries, including the U.S. Several of the 13 significant genes identified by researchers had previously been linked to other illnesses, including autoimmune diseases.

One example is the gene TYK2. Variants of this gene can increase susceptibility to infections by other viruses, bacteria and fungi, the studys authors write. Individuals who carry certain mutations in TYK2 are at increased risk of being hospitalized or developing critical illness from COVID-19. Another example is the gene DPP9. The authors found a variant in this gene that increases the risk of becoming critically ill with COVID-19. It is the same variant that can increase the risk of a rare pulmonary disease characterized by scarring of the lung tissue.

This study is important not only for advancing our understanding of human susceptibility to COVID-19; it also underlines the value of global collaborations for clarifying the human genetic basis of variability in susceptibility to infectious diseases, states a supplemental article to the study published in Nature.

Children represent a growing share of COVID-19 infections in the United States, while severe illness from the coronavirus remains rare among young kids and adolescents. Researchers caution, however, that studies are needed to determine long-term health effects of COVID-19 on children.

According to the American Academy of Pediatrics (AAP), children accounted for about 2 percent of infections at the onset of the pandemic last year. By the end of May of this year, kids accounted for 24 percent of new weekly infections, the AAP said. The cummulative percentage of COVID-19 cases involving children is about 14 percent, the organization states.

More than 4 million children have tested positive for COVID-19 in the U.S., 18,500 were hospitalized and 336 have died from the disease, according to the latest update from the AAP.

At this time, it still appears that severe illness due to COVID-19 is rare among children, the AAP states. However, there is an urgent need to collect more data on longer-term impacts of the pandemic on children, including ways the virus may harm the long-term physical health of infected children, as well as its emotional and mental health effects.

The U.S. Centers for Disease Control and Prevention (CDC) recommends everyone 12 years and older should get a COVID-19 vaccination to help protect against COVID-19. At this time, children 12 years and older are able to get the Pfizer-BioNTech COVID-19 vaccine. In May, the CDC and U.S. Food and Drug Administration approved the use of the Pfizer vaccine for adolescents after a clinical trial involving 2,260 12-to-15-year-olds found that the Pfizer-BioNTEch vaccines efficacy was 100 percent. This official CDC action opens vaccination to approximately 17 million adolescents in the United States and strengthens our nations efforts to protect even more people from the effects of COVID-19, stated CDC Director Rochelle Walensky in a statement.

Tags: COVID-19, COVID-19 vaccines

See the rest here:
COVID-19 Roundup: The Unvaccinated Fuel Hospitalizations; Genetic Link to Severe Illness; and Children's Infection Rate - Baptist Health South Florida

Marion scientists awarded grant to identify molecular mechanisms that drive cancer – Marion Star

MARION -A group of Ohio State University Marion faculty researchers were recently awarded a $156,000 federal grant from the National Institutes of Healths National Cancer Institute for research in the role of chromatin remodeling factors in DNA double strand break repair.

Assistant Professor of Molecular GeneticsDr. Ruben Petreaca, Associate Professor of Chemistry and BiochemistryDr Ryan Yoder, and Assistant Professor of Chemistry and BiochemistryDr. Renee Bouley are collaborating toward the goal of identifying molecular mechanisms that drive cancer, which if successful would make significant impact in the field of cancer research. The funds from the grant cover primarily undergraduate research salaries and materials between May 1, 2021, and April 30, 2023.

When considering the groups research, Petreaca shared that one challenge to understanding the genetic change in cancer cells is the complexity of the different processes that participate in DNA damage repair.

Errors in some of these repair processes cause accumulation of various forms of DNA damage that eventually leads to cellular transformation and cancer, said Petreaca.

Here we propose novel protein modeling and genetic analysis to understand the interactions between various repair complexes and determine the roles they play in promoting accurate repair, he added.

As a scientist and researcher, Petreaca boiled it down to two basic conceptsthe importance of grants to the discovery process and involving students in research.

It means we can keep doing science, said Petreaca. More importantly, this grant will be used exclusively to fund undergraduate research at Marion.

Yoder echoed Petreacas sentiment about the funding directly benefitting undergraduate research and added his thoughts on the unique aspect of collaboration between different departments and majors working toward a unified goal.

I think its important to stress the interdisciplinary nature of this work, said Yoder.We have faculty with three very different backgrounds (molecular genetics, biochemistry, molecular modeling) who are all bringing our own strengths to this effort.

That means our students who work on this project will be exposed to many different research methods and techniques, he added, which can only benefit them as they move forward in their educational journey.

Having the resources and backing of a tier 1 research university, while having the advantages of a small campus setting to enhance such a collaborative project is at the core of what Ohio State Marion is all about, Yoder shared.

The intimate setting of Ohio State Marion, along with (the resources available at) our Science & Engineering Building, Yoder said, allows for such interdisciplinary research to thrive and provide our students such opportunities to participate in cancer research.

According to Bouley, even before she officially began her tenure on campus, she began working on a project with Dr. Petreaca and got advice on purchasing start-up equipment.

I love how collaborative the science faculty are at Ohio State Marion, said Bouley.

It has been so helpful to team up with other faculty in different fields of expertise to tackle challenging problems such as understanding what causes cancer to develop, she said.

Much like Petreaca and Yoder, for Bouley the grant is about supplying their research materials and hiring bright and energetic young minds who will greatly benefit their future education and career by being involved in research on the undergraduate level.

This grant is currently supporting several undergraduate students and most importantly for my lab, Bouley said, research supplies to be able to conduct biochemistry experiments.

The recent Pelotonia fellow Lauren Frank is currently working on purifying proteins and modeling protein-protein interactions as part of this grant, she explained.

Lauren Frank is the campuss third Pelotonia Undergraduate Fellowship recipient in the past four years, demonstrating the campuss strong science programs and the level of faculty engagement with students in interdisciplinary research.

View original post here:
Marion scientists awarded grant to identify molecular mechanisms that drive cancer - Marion Star

Fact Check-Fruit juices and coffee cannot produce a positive test result for COVID-19 – Reuters

Updated to correct paragraph formatting

Social media users claiming that fruit juices and coffee have tested positive for COVID-19 have misunderstood how lateral flow devices (LFDs) work. Videos allegedly showing a positive test result actually reveal what happens when devices are degraded by using substances other than those intended.

Examples of the claim can be found here, here here.

Imagine just how many hundreds of thousands of fake positives have been reported as actual covid, one individual said in a Facebook post (here).

Many of the users have tested LFDs with substances other than saliva to prove they are ineffective. They include examples of the devices showing two pink lines, indicative of a positive COVID-19 result.

However, this is misleading.

The beverages and other solutions used do not contain the COVID virus, Professor Mark Lorch, professor of public engagement and science communication and interim head of department for chemistry, biochemistry and chemical engineering at the University of Hull, told Reuters by email.

He said that while results might appear to be positive, they reveal something else. Instead, the acidity of the juices, soft drinks, coffee etc. disrupt the delicate antibodies on the test devices and so corrupt the test results.

Inside a lateral flow test, there is a strip known as the conjugation pad where antibodies are attached to gold nanoparticles. Those antibodies bind with virus particles should the test encounter the coronavirus (Lateral Flow Test Teardown). After taking a swab from the throat and nose, the sample is mixed with a buffer to ensure optimum pH before dripping it onto the strip (here , here , here and here).

These tests rely on molecular components such as the antibodies and functionalised nanoparticles being able to bind and this is determined by electrostatic interactions between the components, Andrea Sella, a professor of chemistry at University College London (UCL), told Reuters.

When it comes to biological components, most of them have components that are very pH sensitive. For example, if you change the pH, you can completely change the charge of a protein from, say, positive to negative and the result is that it will not stick correctly.

Sella added that it was therefore unsurprising that LFDs were disrupted when testing substances such as Coca-Cola and orange juice, considering the pH is significantly more acidic than biological fluids.

The two resulting red lines on an LFD do not have any meaning in these circumstances, he said, because youve wrecked the underlying chemistry that allows you to do the delicate detection you want.

Moreover, the US Food and Drug Administration (FDA) has warned that there is potential for false positive results with antigen tests, including when users do not follow the instructions (here).

A clinical evaluation into lateral flow antigen tests by the University of Oxford and Public Health England (PHE) found that the tests detect the most infectious COVID cases (here, here, here).

Reuters previously fact-checked the claim that Coca-Cola produces a positive COVID-19 test (here).

False. Fruit juices and coffee do not test positive for COVID-19. The acidity in such substances corrupts lateral flow devices.

This article was produced by the Reuters Fact Check team. Read more about our fact-checking work here .

Excerpt from:
Fact Check-Fruit juices and coffee cannot produce a positive test result for COVID-19 - Reuters

Virginia Tech researchers receive $2.7 million grant to study mosquito’s biological timing – News-Medical.Net

Mosquitoes may be small, but they are a formidable foe. Not only can they smell over 400 chemicals that we emit and detect the carbon dioxide we breathe out, but they can even adapt their daily behavior in response to our own.

With the help of a $2.7 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), researchers at Virginia Tech are now investigating how mosquitoes adjust their olfactory, or smelling, rhythms in response to changes in our own daily activity.

Mosquitoes are sometimes described as the deadliest animal on Earth. What we are seeing is an increase in the rate of mosquitoes that become resistant to insecticides and have some other level of behavioral resistance. We need another tool or other tools to control mosquito populations."

Clment Vinauger, Principal Investigator on the Project and Assistant Professor, Department of Biochemistry, College of Agriculture and Life Sciences

Vinauger alongside assistant professor Chlo Lahondre and university distinguished professor Jake Tu, both from the Department of Biochemistry in the College of Agriculture and Life Sciences and affiliated faculty members of the Center for Emerging, Zoonotic, and Arthropod-borne Pathogens, an arm of the Fralin Life Sciences Institute, received the grant to support a five-year project to study mosquito's biological timing, or chronobiology.

The research will look at the molecular and cellular levels of the mosquito brain to find what allows mosquitoes to adapt and finetune their biological rhythms.

"Mosquitoes have rhythms, exactly like us," said Lahondre, who is also an affiliated faculty member of Fralin's Global Change Center. "We are very active during the day and then we go to sleep. For mosquitoes, we don't know a lot about their biological rhythm, so we are trying to understand how they process information at different times of the day and what is going on in their brain."

The specific mosquito species being studied is Aedes aegypti, a primary vector for Zika, dengue, and yellow fever. These invasive mosquitoes prefer to feed on people and live throughout the Southern United States, including Virgina.

With a more urbanized environment and a changing climate, the ranges of these mosquitoes and other mosquito species could expand over the coming years. Adding to that, large populations of mosquitoes are becoming both physiologically resistant to insecticides and behaviorally resistant to other control methods like bed nets.

"With climate change, there is a potential impact on mosquitoes' geographic distribution," Lahondre said. "As temperatures are rising, mosquitoes can move north, and that exposes people to the potential diseases that they can transmit."

Understanding Mosquito Behavior to Prevent Disease SpreadPlay

Video Credit: Virginia Tech

Mosquitoes are resilient beings. No matter how many showers we may take, mosquitoes can still smell and find us. As found by Vinauger and Lahondre's past research, mosquitoes can remember host smells and effectively track their victims.

To be the most efficient bloodsuckers on earth, mosquitoes also need to be active most when they can find a meal the easiest. That time is usually when we are most vulnerable and easy to access, which often aligns with our daily activities and circadian rhythms.

Mosquitoes also experience biological rhythms with their sense of smell. At one stage of the day, they reach a low point in odor sensitivity that eventually rises to a smelling peak. Their ability to detect and process host odors then declines, just as our senses decline late at night.

The more in tune their rhythm is with our availability as hosts, the more mosquitoes can feed and the more disease is spread.

Understanding what molecular and cellular processes underpin these rhythms could prove crucial in the fight against mosquitoes that cause disease outbreaks.

"What we are proposing here is to try to understand how mosquitoes keep out-smarting our control strategies," said Vinauger, who is also an affiliated faculty member of the Fralin Life Sciences Institute and Center for Emerging, Zoonotic, and Arthropod-borne Pathogens. "How do they synchronize to a new human environment or the fact that their host is available only at certain times compared to others?"

Using miniature mosquito-helmets that track brain activity in a virtual reality setting, the team of researchers will be able to determine how mosquitoes modulate their olfactory rhythms and their behavioral rhythms in response to host cues.

The research will also investigate how circadian clocks control mosquitoes' brain and antenna activity by "knocking out" the gene that controls a mosquito's sense of time, effectively creating an arrhythmic, mutant mosquito.

Put together with single-cell sequencing of the mosquito brain, the researchers will be able to identify where and what molecules or cells control how mosquitoes synchronize their rhythms with ours.

"If we can better understand how they work, we can have a better set of tools to use for their control," Lahondre said. "Understanding why they bite and how they process information at a specific time of the day can lead to finding key information for mosquito control."

As mosquitoes become more resistant to insecticides and spread at a rapid rate, finding new targets to disrupt their feeding habits is all the more important.

Through this NIH's NIAID grant, Vinauger and his team are hoping to find any rhythmic targets that mosquito control professionals can exploit. All it takes is finding out just what makes a mosquito tick.

Go here to read the rest:
Virginia Tech researchers receive $2.7 million grant to study mosquito's biological timing - News-Medical.Net